Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CHOP versus R-CHOP in previously untreated CD20-positive diffuse large B-cell lymphoma
2010-024194-39Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of obinutuzumab and rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Feb 2011; status: completed.
02
Drugs
obinutuzumabrituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2010-024194-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024194-39.